Cohesion and empowerment! Shandong Guoxin and his entourage visited Yinfeng Cryogenic Medical Research Center for visits and exchanges
Release time:
2023-09-05
On September 5th, Zhou Peng and Zhao Quanan, general managers of Jinan Yinfeng Wealth Center of Shandong International Trust Co., Ltd., and Yang Qin, an expert of Beijing family office trust, visited the Cryogenic Medicine Research Center of Shandong Yinfeng Life Science Research Institute.
During the visit, Shandong Guoxin and his entourage learned in detail about the scientific research progress and application prospects of cryogenic medicine, learned for the first time about the history of Yinfeng's life extension program and the story behind "Asia's first human cryopreservation", and expressed concern and recognition for this forward-looking and challenging research project, and looked forward to the future vision and bright future of cryogenic medicine.
Subsequently, at the symposium, the Yinfeng cryogenic medical team comprehensively introduced the operation, business sectors and scientific research development of Yinfeng Group and the Cryogenic Medical Research Center; Shandong Guoxin and his entourage introduced the comprehensive strength and business layout of Shandong Guoxin Company in depth. At the same time, the two sides discussed the integration of resource advantages and service models, in order to find opportunities, promote model innovation, empower each other, and provide better services for members of both sides.
Through this visit and exchange, the two sides initially reached a cooperation intention, which laid a good foundation for the next step of cross-industry cooperation.
相关介绍
Shandong International Trust Co., Ltd. (hereinafter referred to as "Shandong Guoxin"), established in 1987, is a non-bank financial institution approved by the People's Bank of China and the People's Government of Shandong Province. As a comprehensive financial service institution controlled by Luxin Group, Shandong Guoxin was listed on the Hong Kong Stock Exchange in December 2017, becoming the first mainland trust to land in the international capital market and the first Hong Kong stock trust.
Shandong Guoxin has always adhered to the principle of seeking progress while maintaining stability and improving quality, comprehensively using a variety of financial tools to serve economic and social development, effectively grafting the money market, capital market and real economy, and building a development pattern of "rooted in Shandong, radiating the whole country and going international", and has won the highest grade A in China's trust industry rating and the highest AAA grade in the performance evaluation of local financial enterprises in Shandong Province for many times, and has developed into a comprehensive financial and wealth management service provider with leading comprehensive strength and high brand reputation.
Latest developments
Over the two days, the symposium was not only a collision of ideas but also seeds sown to advance social progress in life culture. The Shandong Yinfeng Life Science Public Welfare Foundation will continue to use technology as wings and culture as roots, collaborating with all sectors of society to enhance the quality of life for the Chinese people and build a human-centered life care system.
According to recent announcements by the Jinan Municipal Bureau of Science and Technology, 11 outstanding achievements from Jinan have been included in the 2025 "Shandong Outstanding Achievements Report" project. Among them is the globally first-of-its-kind ovarian tissue dual-activation technology developed by Shandong Silver Med Life Science Research Institute (Jinan).
Recently, Frigid Zone Medicine, an authoritative international journal in the field of cryomedicine, published an important review titled "Advances in the Detection Methods for Assessing the Viability of Cryopreserved Samples". Written by the team of Yinfeng Cryomedical Research Center, the article systematically reviews and analyzes various detection techniques currently used to evaluate the viability of cryopreserved cells, tissues, and organs. It also proposes key directions from the perspectives of methodological integration and future instrument development, offering crucial theoretical support and practical guidance for the long - term cryopreservation of complex tissues and organs.
Recently, the "Novel Technology for Ultra-Low Temperature Cryopreservation, Activation, and Transplantation of Human Ovarian Tissue," developed through a collaborative effort between Shandong Yinfeng Life Science Research Institute and Beijing University of Chinese Medicine Shenzhen Hospital, has been awarded the 2025 Shandong Refrigeration and Air Conditioning Science and Technology Award. This groundbreaking technology pioneers a new pathway for female fertility preservation, marking a significant leap in China’s interdisciplinary advancements in reproductive medicine and cryobiology.
On May 19, a delegation from the Chinese Training Workshop for Government Officials of Developing Countries visited the exhibition hall of Yinfeng Biological Group's Cryomedicine Research Center. Government officials from multiple countries gained in-depth insights into Yinfeng’s innovative achievements in cryobiomedicine, cell storage, genetic technology, and other fields. They engaged in discussions with the delegation on technology transfer and international cooperation, contributing to the building of a global community with a shared future for humanity.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
